New Study Demonstrates vMap Associated with Significantly Improved Outcomes in Atrial Fibrillation Treatment
March 21, 2023

New Study Demonstrates vMap Associated with Significantly Improved Outcomes in Atrial Fibrillation Treatment

Use of vMap during complex atrial fibrillation (AF) ablation was associated with significantly improved freedom from atrial arrhythmias compared with standard-of-care pulmonary vein isolation.

The study found that additional AF driver site ablation guided by vMap was associated with an 87.5% freedom from all atrial arrhythmias compared with the control arm’s 58.0% arrhythmia-free survival (p=0.043).

The results will be presented at the Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium on Saturday, March 25, in La Jolla, California.

Background image of a crowd watching a presentation on stageBackground image of a well lit office spaceBackground image of abstract, dimensional, curvy linesBackground image of abstract blue transparent shapesBackground image of a clinic waiting room
November 21, 2022

New AF and Congenital Heart Disease Data on vMap Presented at APHRS

New data was presented that demonstrated vMap's potential utility in patients with adult congenital heart disease and refractory atrial fibrillation at the recent Annual Asia Pacific Heart Rhythm Society (APHRS) Scientific Session.

“These initial clinical results that show successful mapping with vMap in complex cases are promising," said Sutton Fox M.D., UC San Diego Health. "Although additional studies are needed, we are optimistic that future clinical results may reinforce vMap’s usability for a broader range of patients, which ultimately has the potential to improve patient outcomes for millions of people with adult congenital heart disease and refractory atrial fibrillation.”

October 10, 2022

New Data Demonstrates vMap Reduces Procedural Duration, Fluoroscopy Use, and Cost 

In the presentation titled Forward-Solution Computational Arrhythmia Mapping is Associated with Decreased Procedural Time, Fluoroscopy Use, and Cost, Toomu presented findings from a retrospective, case-control study evaluating the hypothesis that non-invasive computational ECG mapping reduces overall procedure time, fluoroscopy use, and cost in the EP lab setting. The poster presentation won first place in the research category.

vMap exhibited a reduction in total procedure duration of 68 minutes (227±54 vs. 295±77 minutes, p<0.001), reduction in fluoroscopy time of 16.3 minutes (18.4±13.9 vs. 34.7±16.6 minutes, p<0.001), and EP lab costs ($2,267). Use of vMap was also associated with a reduced use of 64-electrode basket catheters in atrial fibrillation ablation cases (p=0.025)

September 7, 2022

Circulation: Arrhythmia and Electrophysiology Publishes vMap Clinical Data

Circulation has published a peer-reviewed manuscript of the clinical data from a study evaluating the accuracy vMap®. The study shows 97.3% accuracy in identifying arrhythmia source locations in nine atrial and ventricular arrhythmias and pacing types across all four heart chambers. 

The article titled, “Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study” was authored by researchers and cardiologists at the Department of Medicine at the University of California San Diego, Veterans Affairs San Diego Healthcare System, Mills Peninsula Medical Center, Medical University of South Carolina, Katherine Kacena Consulting, Technomics Research, the Department of Bioengineering at the University of California San Diego, and Vektor Medical, Inc.

August 23, 2022

Vektor Draws Two Seasoned MedTech Experts

Vektor today announced the appointment of two seasoned medtech professionals – Tim Laird as Vice President of Sales and Kathryn Wilamowski as Senior Manager, Quality Systems.

Tim has 20 years of experience launching and driving sales for innovative medical device and biotechnology products. In his role at Vektor, he leads the commercial sales strategy and execution for vMap while overseeing the field team. Kathryn is an industrial engineer with over 12 years of medical device quality engineering and assurance experience including FDA, ISO and EU MDR regulations compliance.

August 2, 2022

Vektor Bolsters Team to Accelerate Roll-Out of Computationally-Intelligent Technology

Vektor today announced the appointment of three key executives. The appointments, which come as Vektor prepares to expand the commercial availability of its vMap technology in the U.S., are Joe Braidwood as Chief Strategy Officer, Christian David Márton, Ph.D., as Vice President of Technology and Averee Chang as Vice President of Product.

“Through its early commercial success, we've seen that vMap has the potential to transform arrhythmia care," said Rob Krummen, CEO. "Joe, Averee and Christian are leaders in their respective fields, with distinct perspectives that will help drive our vision forward. I’m thrilled to welcome them to the team and look forward to working closely together through this exciting phase of our journey."

June 22, 2022

Vektor Appoints Rob Krummen as CEO to Accelerate Vision

Vektor Medical today announced the appointment of Rob Krummen as CEO.

With nearly two decades of experience leading and advising corporations, nonprofits, institutions of higher education and state entities, Rob is uniquely qualified to lead the company in this new capacity. Most recently, he served as president and chief operating officer at Vektor, where he led clinical, regulatory, engineering, and operations. As CEO, Rob intends to continue overseeing these efforts, while spearheading the growth of the company’s commercial and sales teams.

Rob’s appointment comes at a pivotal time as Vektor transitions to a commercial company and focuses on its pilot roll-out of vMap™, its easy-to-use and non-invasive cardiac arrhythmia mapping platform, at select cardiovascular centers of excellence across the country, before making it more widely available.

June 17, 2022

In The News: MedTech Strategist

Vektor Medical Aims to Change the Map of Atrial Fibrillation.

“At the recent Heart Rhythm Society meeting, Vektor Medical reported unprecedented rates of success at mapping sources of arrhythmias with vMap, a noninvasive computational modeling system that reveals potential hot spots in less than three minutes”

May 5, 2022

In The News: UC San Diego News

Arrhythmia Mapping Technology Demonstrates Positive Clinical Results.

April 28, 2022

vMap Clinical Validation Study Shows 97.3% Mapping Accuracy for Atrial and Ventricular Arrhythmias

Vektor Medical today announced positive results from its clinical validation study evaluating the accuracy of cardiac mapping with vMap. The study achieved statistically significant results of 98.7% in accurately identifying the regional arrhythmia source location for premature ventricular complex (PVC) and ventricular tachycardia (VT), 96.9% in accurately identifying the regional arrhythmia source for the arrhythmias and pacing types studied, and 97.3% segment mapping accuracy in all nine arrhythmia and pacing types included. 

The study results exceeded the pre-specified accuracy goals for arrhythmia source and pacing site localization, demonstrating vMap’s reliability as an accurate, non-invasive cardiac mapping tool. 

Results from the study will be presented at Heart Rhythm 2022 on April 29, 2022. 

April 4, 2022

In The News: Medgadget

vMap Mapping Technology for Cardiac Arrhythmias: Interview with Mike Monko, CEO of Vektor Medical.

February 22, 2022

In The News: ABC 10 News

UC San Diego doctor creates new way to diagnose irregular heartbeat. vMap system uses ECG to create 3D image of heart.

February 14, 2022

UC San Diego Health Is The World's First Hospital System to Offer vMap

Vektor Medical announced UC San Diego Health as the first hospital system in the world to offer its recently FDA cleared vMap.  

"We are committed to providing the most advanced cardiac arrhythmia care for our patients and are enthusiastic about the opportunity to improve the efficacy and safety of the ablations at UCSD using vMap. We anticipate that vMap’s non-invasive arrhythmia source mapping will enable our team to accurately identify and quickly target arrhythmia sources, which we hope will minimize the need for repeat procedures and reduce risk for patients.” Dr. Farshad Raissi, UC San Diego Health

vMap is the first technology that identifies potential arrhythmia source locations anywhere in the heart in less than three minutes using only 12-lead electrocardiogram data. The company is rolling out the technology at select cardiovascular centers of excellence across the country over the coming year before making it more widely available.

November 9, 2021

Vektor Medical Receives FDA 510(k) Clearance for vMap™

Vektor Medical announced today that its computational ECG mapping system, vMap, has received FDA 510(k) clearance.  

vMap is designed to map potential arrhythmia sources (hot spots) associated with stable or unstable arrhythmias anywhere in the heart, in less than three minutes using only ECG data. Following clearance, vMap will be commercially available to sites across the U.S.

“With vMap we are changing how electrophysiologists think about mapping. Our goal is to increase first-pass success rates, lower risk, and decrease the current cost burden of ablation on the healthcare system.”
Vektor Medical CEO Mike Monko

September 9, 2021

vMap™ reported as feasible and effective as part of a non-invasive workflow for arrhythmia management when using stereotactic ablative radiotherapy

A peer-reviewed article published by the Heart Rhythm Society’s journal Heart Rhythm O2 concludes that Vektor’s Computational ECG Mapping System (vMap™) and protocol-based respiratory gating may help facilitate radioablation planning and maintain efficacy during therapy.

The prospective, dual-site study, led by Dr. Gordon Ho, reported that a new non-invasive workflow using vMap™ may help facilitate the radioablation planning workflow. The study concluded that radio-ablation using vMap’s 12-lead ECG mapping and respiratory gated delivery may provide short-term safety and maintain efficacy during therapy in patients with advanced structural heart disease and refractory ventricular tachycardia (VT).

May 1, 2021

vMap's Role in Optimizing Non-Invasive Radio-Ablation Therapy presented at ACC.21 and THRS 2021.

A dual-center study reported that vMap, as part of a new, non-invasive workflow, improved efficiency and precision for radio-ablation therapy in these study subjects. The study showed that the radio-ablation administered as a part of the enhanced workflow also significantly reduced ICD shocks for patients receiving the therapy. Presented by its lead author Dr. Gordon Ho, at American College of Cardiology 2021 and the Taiwan Heart Rhythm Society 2021 (THRS), the research won first prize in the “Clinical - Ventricular Arrhythmias/Cardiac Implanted Electronic Device” category at THRS. As stated at the ACC and THRS conferences, the study concluded that the simplified, non-invasive workflow, involving vMap, was “Feasible, Efficient, Precise, Effective, [and] Safe”.

April 1, 2021

The feasibility of using vMap™ in patients after COVID-19 Infection presented at THRS 2021.

COVID-19 is associated with myocardial inflammation which may cause or exacerbate arrhythmias. A study led by Dr. David Krummen was presented at the Taiwan Heart Rhythm Society - Cutting-Edge Care for Heart Rhythm on April 17-18, 2021. The study reports that use of vMap™ computational 12-lead ECG analysis was able to provide arrhythmia insights beyond those available from a standard 12-lead ECG in patients following COVID-19 infection.

December 1, 2020

Vektor Medical Initiates Clinical Study of vMap™

Vektor Medical, Inc. announced the start of its clinical study to evaluate vMap™. Using patients who have previously undergone a clinically-indicated electrophysiology study and successful ablation, the purpose of this study is to clinically validate the use of vMap™ in providing arrhythmia/pacing hotspots for analysis by a physician. vMap™ has been designed as the next generation in arrhythmia mapping. This non-invasive, rapid technology helps unlock the patient’s ECG, providing information on arrhythmias in all four heart chambers. Vektor’s study will evaluate vMap™ across a variety of atrial and ventricular arrhythmias, including atrial and ventricular fibrillation.

October 1, 2020

Vektor’s vMap™ Technology Used Alongside SAbR Planning Software (Varian, Palo Alto, CA) for Non-Invasive Mapping and Radio-ablation of Refractory Ventricular Tachycardia

Life-threatening heart rhythm disorders such as ventricular tachycardia may be eliminated using cutting-edge, non-invasive technology as an alternative to standard invasive catheter ablation procedures, in some cases. In an abstract and associated poster published at the American College of Physicians’ Southern Regional Conference, researchers report successful use of vMap™ technology to guide stereotactic radiotherapy to destroy diseased heart tissue. Researchers report that this non-invasive mapping and ablation has “shown tremendous promise in recent years.” Importantly, for this patient, his “shock burden decreased from 34 ICD shocks in the 6 months preceding … therapy to 0 ICD shocks in the 11 months after treatment. His quality of life improved significantly, and he has resumed an active lifestyle”.

May 28, 2020

Vektor Medical, Inc. Chosen as a San Diego Venture Group 2020 Cool Company

Vektor has been selected as one of San Diego Venture Group’s ‘Cool Companies’ for 2020.  Connect w/ San Diego Venture Group (SDVG) promotes the formation, funding, and development of innovative new ventures in the San Diego community.  "We help innovative companies thrive so they can make a meaningful impact on the economic development of the region, and together create a world-class tech ecosystem," Mike Krenn, CEO of Connect. SDVG’s Cool Companies list highlights the fastest-growing, most exciting startups in Southern California.

May 1, 2020

Computer-Based 12-Lead ECG Analysis Accurately Maps Ventricular Locations

Researchers, in an abstract and associated poster published in the Heart Rhythm Society’s journal Heart Rhythm, find that computer-based analysis of 12-lead ECG accurately mapped 93% of known ventricular locations to the exact ventricular segment.  The computer-based analysis required only 3 minutes, plus or minus 2 minutes, per ECG.